Can retroperitoneal lymphadenectomy be omitted in some patients after chemotherapy?

Richard Foster, J. P. Donohue

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The advances in the therapy of high-volume stage II and stage III testicular cancer have been largely due to the development and success of cisplatin-based chemotherapy. Though patients with low- to moderate-volume stage II disease historically were curable with radical retroperitoneal lymph node disssection, patients with higher volumes of metastatic disease were not curable with surgery alone. The advent of cisplatin-based chemotherapy in the 1970s has allowed many of these patients with higher-volume metastatic disease to be cured. Though chemotherapy clearly plays the major role in the therapy of these patients, surgery after chemotherapy has been complimentary in the overall chance for cure of these patients.

Original languageEnglish (US)
Pages (from-to)479-484
Number of pages6
JournalUrologic Clinics of North America
Volume25
Issue number3
StatePublished - 1998
Externally publishedYes

Fingerprint

Lymph Node Excision
Drug Therapy
Cisplatin
Testicular Neoplasms
Lymph Nodes
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

Can retroperitoneal lymphadenectomy be omitted in some patients after chemotherapy? / Foster, Richard; Donohue, J. P.

In: Urologic Clinics of North America, Vol. 25, No. 3, 1998, p. 479-484.

Research output: Contribution to journalArticle

@article{0070dd4116934af48891ca98ad3dd7dd,
title = "Can retroperitoneal lymphadenectomy be omitted in some patients after chemotherapy?",
abstract = "The advances in the therapy of high-volume stage II and stage III testicular cancer have been largely due to the development and success of cisplatin-based chemotherapy. Though patients with low- to moderate-volume stage II disease historically were curable with radical retroperitoneal lymph node disssection, patients with higher volumes of metastatic disease were not curable with surgery alone. The advent of cisplatin-based chemotherapy in the 1970s has allowed many of these patients with higher-volume metastatic disease to be cured. Though chemotherapy clearly plays the major role in the therapy of these patients, surgery after chemotherapy has been complimentary in the overall chance for cure of these patients.",
author = "Richard Foster and Donohue, {J. P.}",
year = "1998",
language = "English (US)",
volume = "25",
pages = "479--484",
journal = "Urologic Clinics of North America",
issn = "0094-0143",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Can retroperitoneal lymphadenectomy be omitted in some patients after chemotherapy?

AU - Foster, Richard

AU - Donohue, J. P.

PY - 1998

Y1 - 1998

N2 - The advances in the therapy of high-volume stage II and stage III testicular cancer have been largely due to the development and success of cisplatin-based chemotherapy. Though patients with low- to moderate-volume stage II disease historically were curable with radical retroperitoneal lymph node disssection, patients with higher volumes of metastatic disease were not curable with surgery alone. The advent of cisplatin-based chemotherapy in the 1970s has allowed many of these patients with higher-volume metastatic disease to be cured. Though chemotherapy clearly plays the major role in the therapy of these patients, surgery after chemotherapy has been complimentary in the overall chance for cure of these patients.

AB - The advances in the therapy of high-volume stage II and stage III testicular cancer have been largely due to the development and success of cisplatin-based chemotherapy. Though patients with low- to moderate-volume stage II disease historically were curable with radical retroperitoneal lymph node disssection, patients with higher volumes of metastatic disease were not curable with surgery alone. The advent of cisplatin-based chemotherapy in the 1970s has allowed many of these patients with higher-volume metastatic disease to be cured. Though chemotherapy clearly plays the major role in the therapy of these patients, surgery after chemotherapy has been complimentary in the overall chance for cure of these patients.

UR - http://www.scopus.com/inward/record.url?scp=0031928195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031928195&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 479

EP - 484

JO - Urologic Clinics of North America

JF - Urologic Clinics of North America

SN - 0094-0143

IS - 3

ER -